Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

Inclusion Criteria

Concurrent Medication:

Required:

* PCP prophylaxis consisting of Bactrim, aerosolized pentamidine, or dapsone.

Recommended:

* Antiemetic therapy within 30 minutes of chemotherapy.

Allowed:

* Antiretroviral medication after two cycles of chemotherapy, provided the patient has not experienced grade 3 neutropenia while on chemotherapy or on previous antiretroviral therapy.
* Acetaminophen and/or nonsteroidal anti-inflammatory agents.
* Bone marrow-suppressive agents, such as ganciclovir, Fansidar, Bactrim, and dapsone.
* Maintenance therapy for chronic opportunistic infection.

Concurrent Treatment:

Allowed:

* Cranial irradiation (2400 rads) for patients with CNS involvement.

Patients must have:

* Documented HIV infection or diagnosis of AIDS.
* Hodgkin's disease.
* Consent of parent or guardian and have care directly supervised by a pediatric oncologist if under 18 years of age.

Prior Medication:

Allowed:

* Maintenance therapy for opportunistic infections.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Second primary cancer other than Kaposi's sarcoma that does not require systemic therapy, nonmelanomatous skin cancer, Bowen's disease, or carcinoma in situ of the cervix.
* Acute, active bacterial or opportunistic infection requiring ongoing therapy if such therapy has been initiated within the past 2 weeks.
* Known hypersensitivity (e.g., anaphylactoid reaction, bronchospasm) to E. coli-derived proteins.

Prior Medication:

Excluded:

* Prior chemotherapy for Hodgkin's disease.
* Antiretroviral therapy within 2 weeks prior to study entry.

Prior Treatment:

Excluded:

* Prior radiotherapy for Hodgkin's disease.